Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Relapsing Remitting ◽

Disease Modifying ◽

PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2018.09.2021 ◽

2018 ◽

Vol 21 ◽

pp. S338 ◽

Cited By ~ 1

Author(s):

W Herring ◽

IG Gould ◽

G Casamassima ◽

T Dort ◽

Y Zhang ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Real World ◽

Inadequate Response ◽

Real World Data ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

PND73 - THE IMPACT OF MODELLING SUBSEQUENT TREATMENT ON ESTIMATES OF COST-EFFECTIVENESS: AN ANALYSIS OF DISEASE-MODIFYING TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED KINGDOM

Value in Health ◽

10.1016/j.jval.2018.09.2039 ◽

2018 ◽

Vol 21 ◽

pp. S341

Author(s):

H Phelps ◽

C Treharne ◽

G Ramirez Guevara ◽

E Bertranou

Keyword(s):

Multiple Sclerosis ◽

United Kingdom ◽

Cost Effectiveness ◽

Subsequent Treatment ◽

The United Kingdom ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis ◽

The Impact

A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland

10.26226/morressier.59a3eda8d462b8028d8951ac ◽

2017 ◽

Author(s):

Carlos Acosta

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Real World ◽

Inadequate Response ◽

Real World Data ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

Value in Health ◽

10.1016/j.jval.2018.09.2022 ◽

2018 ◽

Vol 21 ◽

pp. S338

Author(s):

W Herring ◽

IG Gould ◽

L Ruiz ◽

T Dort ◽

Y Zhang ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Real World ◽

Inadequate Response ◽

Real World Data ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.1080/13696998.2016.1258366 ◽

2016 ◽

Vol 20 (3) ◽

pp. 297-302 ◽

Cited By ~ 12

Author(s):

Duygu Bozkaya ◽

Terrie Livingston ◽

Kristen Migliaccio-Walle ◽

Tanner Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1247712 ◽

2016 ◽

Vol 20 (3) ◽

pp. 228-238 ◽

Cited By ~ 10

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Hector Toro-Diaz ◽

Stuart Carroll ◽

Syed Feisal Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost-Effectiveness of Disease Modifying Therapies for The Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.03.1653 ◽

2015 ◽

Vol 18 (3) ◽

pp. A283 ◽

Cited By ~ 2

Author(s):

D. Bozkaya ◽

T.P. Livingston ◽

K. Migliaccio-Walle ◽

S. Mehta ◽

T. Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

PharmacoEconomics ◽

10.2165/00019053-200826070-00008 ◽

2008 ◽

Vol 26 (7) ◽

pp. 617-627 ◽

Cited By ~ 54

Author(s):

Ray Gani ◽

Gavin Giovannoni ◽

David Bates ◽

Belinda Kemball ◽

Steve Hughes ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Highly Active ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Uk ◽

Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2017.08.1948 ◽

2017 ◽

Vol 20 (9) ◽

pp. A723

Author(s):

L Ruiz ◽

H Toro-Diaz ◽

C Cele ◽

L Hernandez ◽

A Harrington

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

PND51 Cladribine Tablets (CT) Versus Other Disease-Modifying Therapies in the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Cost-Effectiveness Analysis.

Value in Health ◽

10.1016/j.jval.2020.08.1376 ◽

2020 ◽

Vol 23 ◽

pp. S632

Author(s):

P. Zięba ◽

D. Pawlik ◽

J. Wieczorek ◽

R. Wojcik ◽

M.P. Kaczor

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽